128 related articles for article (PubMed ID: 8161925)
1. Acute myeloblastic leukemia with minimal myeloid differentiation (FAB AML-M0): a study of eleven cases.
Sempere A; Jarque I; Guinot M; Palau J; García R; Sanz GF; Gomis F; Pérez-Sirvent ML; Senent L; Sanz MA
Leuk Lymphoma; 1993 Dec; 12(1-2):103-8. PubMed ID: 8161925
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy for minimally differentiated acute myeloid leukemia (AML-M0). A report on five cases and review of the literature.
Yokose N; Ogata K; Ito T; Miyake K; An E; Inokuchi K; Yamada T; Gomi S; Tanabe Y; Ohki I
Ann Hematol; 1993 Feb; 66(2):67-70. PubMed ID: 8383541
[TBL] [Abstract][Full Text] [Related]
3. Analysis of treatment failure in patients with minimally differentiated acute myeloid leukemia (AML-M0).
Stasi R; Del Poeta G; Venditti A; Masi M; Stipa E; Dentamaro T; Cox C; Dallapiccola B; Papa G
Blood; 1994 Mar; 83(6):1619-25. PubMed ID: 8123853
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneity of acute myeloblastic leukemia without maturation: an ultrastructural study.
Hamamoto K; Date M; Taniguchi H; Nagano T; Kishimoto Y; Kimura T; Fukuhara S
Ultrastruct Pathol; 1995; 19(1):9-14. PubMed ID: 7770965
[TBL] [Abstract][Full Text] [Related]
5. Acute myeloid leukemia with minimal differentiation. A multiple parameter study.
Cohen PL; Hoyer JD; Kurtin PJ; Dewald GW; Hanson CA
Am J Clin Pathol; 1998 Jan; 109(1):32-8. PubMed ID: 9426515
[TBL] [Abstract][Full Text] [Related]
6. Acute myeloblastic leukemia with minimal myeloid differentiation: phenotypical and ultrastructural characteristics.
Villamor N; Zarco MA; Rozman M; Ribera JM; Feliu E; Montserrat E
Leukemia; 1998 Jul; 12(7):1071-5. PubMed ID: 9665192
[TBL] [Abstract][Full Text] [Related]
7. [Immunocytochemistry in the diagnosis of acute myeloid leukemia (M0)].
Saito M; Kuriyama K; Nagai K; Nonaka H; Hata T; Tusima H; Tabata S; Arimura K; Souda H; Nakamura H
Rinsho Ketsueki; 1994 Nov; 35(11):1297-304. PubMed ID: 7823396
[TBL] [Abstract][Full Text] [Related]
8. Myeloid enzymes profile related to the immunophenotypic characteristics of blast cells from patients with acute myeloid leukemia (AML) at diagnosis.
Klobusicka M; Kusenda J; Babusikova O
Neoplasma; 2005; 52(3):211-8. PubMed ID: 15875082
[TBL] [Abstract][Full Text] [Related]
9. Flow cytometric immunophenotypic characterization of pediatric and adult minimally differentiated acute myeloid leukemia (AML-M0).
Kotylo PK; Seo IS; Smith FO; Heerema NA; Fineberg NS; Miller K; Greene ME; Chou P; Orazi A
Am J Clin Pathol; 2000 Feb; 113(2):193-200. PubMed ID: 10664621
[TBL] [Abstract][Full Text] [Related]
10. Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience.
Tallman MS; Neuberg D; Bennett JM; Francois CJ; Paietta E; Wiernik PH; Dewald G; Cassileth PA; Oken MM; Rowe JM
Blood; 2000 Oct; 96(7):2405-11. PubMed ID: 11001891
[TBL] [Abstract][Full Text] [Related]
11. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
[TBL] [Abstract][Full Text] [Related]
12. [Immunologic characteristics and prognosis of acute myeloid leukemia M1].
Zhao F; Chen Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug; 15(4):687-91. PubMed ID: 17708783
[TBL] [Abstract][Full Text] [Related]
13. Contribution of clonogenic leukemic cell characteristics to therapy outcome in patients with acute myeloblastic leukemia.
Aul C; Heyll A
Haematol Blood Transfus; 1987; 30():356-60. PubMed ID: 3476367
[No Abstract] [Full Text] [Related]
14. [Comparative analysis of 3 therapeutic regimens based on the combination of an anthracycline and cytosine arabinoside for remission induction in myeloblastic leukemia].
Sanz MA; Lorenzo JI; Sanz GF; Martín Aragonés G; Rafecas FJ; Martínez JA; Gomis F
Sangre (Barc); 1988 Dec; 33(6):497-504. PubMed ID: 3247626
[No Abstract] [Full Text] [Related]
15. Clinical importance of CD7 expression in acute myelocytic leukemia. The Japan Cooperative Group of Leukemia/Lymphoma.
Kita K; Miwa H; Nakase K; Kawakami K; Kobayashi T; Shirakawa S; Tanaka I; Ohta C; Tsutani H; Oguma S
Blood; 1993 May; 81(9):2399-405. PubMed ID: 7683218
[TBL] [Abstract][Full Text] [Related]
16. [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children].
Pituch-Noworolska A
Folia Med Cracov; 2001; 42(3):5-80. PubMed ID: 12353422
[TBL] [Abstract][Full Text] [Related]
17. Acute leukemia coexpressing myeloid, B- and T-lineage associated markers: multiparameter analysis of criteria defining lineage commitment and maturational stage in a case of undifferentiated leukemia.
Meckenstock G; Heyll A; Schneider EM; Hildebrandt B; Runde V; Aul C; Bartram CR; Ludwig WD; Schneider W
Leukemia; 1995 Feb; 9(2):260-4. PubMed ID: 7869761
[TBL] [Abstract][Full Text] [Related]
18. Bone marrow biopsy during induction chemotherapy for acute myeloid leukaemia identifies only 50% of patients with resistant disease.
Roberts MM; Juttner CA; To LB; Kimber RJ
Leuk Res; 1988; 12(10):817-21. PubMed ID: 3199841
[TBL] [Abstract][Full Text] [Related]
19. [Prognostic significance of CD7 expression in adult acute myeloid leukemia].
Saito T; Usui N; Dobashi N; Maki N; Asai O; Yano S; Kato A; Watanabe H; Katori M; Nagamine M; Ogihara A; Yamazaki H; Kobayashi T; Tajima N; Kuraishi Y
Rinsho Ketsueki; 1998 Jul; 39(7):481-6. PubMed ID: 9750454
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment prognostic factors for overall survival in primary resistant acute myeloid leukemia.
Colovic N; Tomin D; Vidovic A; Suvajdzic N; Jankovic G; Palibrk V; Djunic I; Djurasinovic V; Virijevic M
Biomed Pharmacother; 2012 Dec; 66(8):578-82. PubMed ID: 23085253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
